TACSTD2 and neoplasm: It is of note that similar observations were recorded by brightfield immunohistochemistry in analyses of partially overlapping sets of pTa tumors in separate studies determining the expression of TROP2 and EpCAM in >10,000 tumors from up to 150 different tumor entities (30, 33).